Thalassemia is an inherited blood disorder characterized by reduced hemoglobin production. It is caused by mutations in genes that encode the alpha or beta globin chains that make up hemoglobin. There are different types of thalassemia depending on which chain is affected, including alpha-thalassemia affecting alpha chains and beta-thalassemia affecting beta chains. Symptoms range from none to severe anemia. Diagnosis involves blood tests like complete blood count and hemoglobin electrophoresis. Treatment depends on severity but may include blood transfusions, iron chelation therapy, and bone marrow transplantation.
This a series of notes on hematology useful for undergraduate and postgraduate medical and paramedical students. Notes are prepared from standard texts and are easy to reproduce in exams.
This a series of notes on hematology useful for undergraduate and postgraduate medical and paramedical students. Notes are prepared from standard texts and are easy to reproduce in exams.
challenges in interpreting abnormal hemoglobin study- the key is to correlate with patient age, ethnicity,RBC indices & morphology findings. Two tier approach for correct characterization of abnormal hemoglobins of HPLC &/or capillary electrophoresis.
Autoimmune hemolytic anemia (or autoimmune haemolytic anaemia; AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to insufficient plasma concentration.
1• Define anemia and it's genetic bases.2• Describe thalassemia and it's genetic bases.3• What is the molecular defects and pathophysiology of thalassemia 4• Describe the diagnostic test that detect genetic mutation of thalassemia 5• Overview of pre-marital screening test.
challenges in interpreting abnormal hemoglobin study- the key is to correlate with patient age, ethnicity,RBC indices & morphology findings. Two tier approach for correct characterization of abnormal hemoglobins of HPLC &/or capillary electrophoresis.
Autoimmune hemolytic anemia (or autoimmune haemolytic anaemia; AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to insufficient plasma concentration.
1• Define anemia and it's genetic bases.2• Describe thalassemia and it's genetic bases.3• What is the molecular defects and pathophysiology of thalassemia 4• Describe the diagnostic test that detect genetic mutation of thalassemia 5• Overview of pre-marital screening test.
This presentation contains an overall review of Thalassemia and its Etiology, Inheritance, Symptoms and treatment
Done by: Faten Al-Sadek , Pharmacy student at Mohammed Al-Mana college for Health Sciences -MACHS
• Thalassemia
• Hemoglobinopathies
• Incidence of thalassemia in Thailand
• Mode of inheritance
• How to name thalassemia ?
• Common types of thalassemia
• Alpha Thalassemia
• Symbolism Alpha Thalassemia
• Classification & Terminology Alpha Thalassemia
• Types of a-thalassemia
• Compound heterozygotes
• Comparison of α Thalassemias
• Beta thalassemias (β thalassemias)
• Types of β Thalassemia
• β Thalassemia Symptoms Include
• Diagnosis of Beta Thalassemia
• Prevention
• What Is The Treatment For Thalassemia
Get here,
1. WHAT IS THALASSEMIA?
2. Molecular Basis of Thalassemia.
3. Types of Thalassemia.
4. - Thalassemia.
5.Types of - Thalassemia.
6. 휷- Thalassemia.
7. Types of 휷- Thalassemia.
8. Thalassemia Syndrome.
9.Treatment
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
2. INTRODUCTION
1. Thalassemia are inherited blood disorders characterized by decreased
hemoglobin production. Symptoms depend on the type and can vary from
none to severe.
2. Thalassemia is caused by mutations in the DNA of cells that make
hemoglobin
3. The mutations associated with thalassemia are passed from parents to
children.
3. • Hemoglobin molecules are made of chains called alpha and beta
chains that can be affected by mutations.
• In thalassemia, the production of either the alpha or beta chains are
reduced, resulting in either alpha-thalassemia or beta-thalassemia.
5. Haemoglobin structural biology
❑Hemoglobins are composed of two pairs of globin chains, each of which contains one
alpha-like (α-like) chain and one beta-like (β-like) chain.
❑Embryonic Hbs are expressed as early as four to six weeks of embryogenesis and disappear
around the eighth week of gestation as they are replaced by fetal Hb. Embryonic Hbs
include:
i. Hb Gower-1, composed of two ζ globins (zeta globins) and two ε globins (epsilon
globins) (ζ2ε2)
ii. Hb Gower-2, composed of two alpha globins and two epsilon globins (α2ε2)
iii. Hb Portland, composed of two zeta globins and two gamma globins (ζ2γ2)
7. Fetal Hb
Fetal Hb (Hb F) is produced from approximately eight weeks of gestation
through birth, It declines during the first few months of life. Hb F is composed
of two alpha globins and two gamma globins (α2γ2).
8. Adult Hb
• Adult Hb (Hb A) is the predominant Hb in children by six months of age and
onward; it constitutes 96-97% of total Hb in individuals without a
hemoglobinopathy. It is composed of two alpha globins and two beta globins
(α2β2).
• Hb A2 is a minor adult Hb that normally accounts for approximately 2.5-3.5%
of total Hb from six months of age onward. It is composed of two alpha
globins and two delta globins (α2δ2).
9. Pathophysiology
• The thalassemias are classified according to which chain of the hemoglobin
molecule is affected.
• In α-thalassemias, production of the α-globin chain is affected, while in β-
thalassemia, production of the β-globin chain is affected.
10. • The β-globin chains are encoded by a single gene on chromosome 11;
α-globin chains are encoded by two closely linked genes on
chromosome 16.
• Thus, in a normal person with two copies of each chromosome, two
loci encode the β chain, and four loci encode the α chain.
12. Alpha-thalassemias
• The α-thalassemias involve the genes HBA1 and HBA2. Two gene loci and so
four alleles exist.
• Two alleles are maternal and two alleles are paternal in origin.
• The severity of the α-thalassemias is correlated with the number of affected
α-globin, more alleles involved, the more severe will be the manifestations
of the disease.
13. Alpha-thalassemias
• Alpha-thalassemias result in decreased alpha-globin production; therefore,
fewer alpha-globin chains are produced, resulting in an excess of β chains in
adults and excess γ chains in newborns.
• The excess β chains form unstable tetramers (called hemoglobin H or HbH of
4 beta chains), which have abnormal oxygen dissociation curves.
14.
15. No of missing alleles Types of alpha thalassemia Symptoms
1 Silent carrier No symptoms
2 Alpha thalassemia trait Minor anemia
3 Hemoglobin H disease Mild to moderate anemia; may lead normal life
4 Hydrops fetalis Death usually occurs in utero or at birth
Types of alpha thalassemia
16. Beta-thalassemia
➢Beta thalassemias are due to mutations in the HBB gene on
chromosome 11, also inherited in an autosomal, recessive fashion.
➢Mutated alleles are called β+ when partial function is conserved and
βo when no functioning protein is produced.
a) β thalassemia major : caused by a βo/βo genotype.
b) β thalassemia intermedia : caused by a β+/βo or β+/β+ genotype.
c) β thalassemia minor : caused by a β/βo or β/β+ genotype.
18. Delta-thalassemia
As well as alpha and beta chains present in hemoglobin, about
3% of adult hemoglobin is made of alpha and delta chains. Just
as with beta thalassemia, mutations that affect the ability of this
gene to produce delta chains can occur.
19. Signs and symptoms
✓Iron overload: People with thalassemia can get an overload of iron in their
bodies, either from the disease itself or from frequent blood transfusions.
✓Infection: People with thalassemia have an increased risk of infection. This is
especially true if the spleen has been removed.
✓Bone deformities: Thalassemia can make the bone marrow expand, which
causes bones to widen. This can result in abnormal bone structure, especially
in the face and skull.
20. Signs and symptoms
✓Enlarged spleen: The spleen aids in fighting infection and filters unwanted
material, such as old or damaged blood cells.
✓Slowed growth rates: anemia can cause the growth of a child to slow down.
✓Heart problems: Diseases, such as congestive heart failure and abnormal
heart rhythms, may be associated with severe thalassemia.
21. Diagnosis of Thalassemia
Thalassemia can be diagnosed via a
• Complete blood count,
• Hemoglobin electrophoresis,
• High-performance liquid chromatography,
• DNA testing,
• Mentzer index.
23. Mentzer index
The index is calculated from the results of a complete blood count.
Mentzer index = MCV, in fL / RBC, in Millions per microliter
If Mentzer index is less than 13, thalassemia is said to be more likely.
If Mentzer index is more than 13, iron-deficiency anemia is said to be
more likely.
24. Management of thalassemia
1. Mild thalassemia: People with thalassemia traits do not require medical or follow-up
care after the initial diagnosis is made.
2. Anemia : People with severe thalassemia require medical treatment. A blood
transfusion regimen was the first measure effective in prolonging life.
3. Growth hormone therapy : There is some evidence that growth hormone replacement
therapy may help to increase the rate at which children with thalassemia grow taller.
25. Management of thalassemia
1. Iron overload : Multiple blood transfusions can result in iron overload. The
iron overload related to thalassemia may be treated by chelation therapy
with the medications deferoxamine, deferiprone, or deferasirox.
2. Bone marrow transplantation : It may offer the possibility of a cure in
young people who have an HLA-matched donor. Success rates have been in
the 80–90% range.